e-learning
resources
Munich 2006
Tuesday 05.09.2006
Lung transplantation: clinical issues
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Substitution therapy in Alpha-1 antitrypsin deficiency after lung transplantation
T. Kohnlein, T. Welte, J. Gottlieb (Hannover, Germany)
Source:
Annual Congress 2006 - Lung transplantation: clinical issues
Session:
Lung transplantation: clinical issues
Session type:
Thematic Poster Session
Number:
4157
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Kohnlein, T. Welte, J. Gottlieb (Hannover, Germany). Substitution therapy in Alpha-1 antitrypsin deficiency after lung transplantation. Eur Respir J 2006; 28: Suppl. 50, 4157
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
The withdrawal of replacement therapy and outcomes in alpha-1 antitrypsin deficiency lung transplant recipients
Source: Eur Respir J, 53 (5) 1900055; 10.1183/13993003.00055-2019
Year: 2019
Screening for alpha-1 antitrypsin deficiency in Polish lung or liver disease patients
Source: Annual Congress 2011 - Lung development and neoplasia
Year: 2011
Exercise intolerance and lung emphysema in alpha-1 antitrypsin deficiency (AATD)
Source: Annual Congress 2010 - Exercise in COPD
Year: 2010
Lung function in relation to emphysema development in alpha-1 antitrypsin deficiency
Source: International Congress 2019 – Insights into physiological diagnostic services
Year: 2019
Alpha-1 antitrypsin deficiency – a potentially fatal disease
Source: International Congress 2017 – Rare and common genetic variants of common and rare airway diseases
Year: 2017
COPD and alpha-1 antitrypsin deficiency emphysema: characteristics and survival after Lung Transplantation
Source: International Congress 2018 – Moving lung transplantation forward
Year: 2018
Alpha-1 antitrypsin deficiency severity and the risk of COVID-19
Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19
Year: 2021
Pulmonary administration of alpha
1
-antitrypsin for the treatment of Alpha
1
-antitrypsin deficiency
Source: Eur Respir J 2003; 22: Suppl. 45, 385s
Year: 2003
Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation
Source: Eur Respir J, 50 (3) 1700962; 10.1183/13993003.00962-2017
Year: 2017
Endobronchial valve treatment in patients with severe emphysema due to alpha-1 antitrypsin deficiency.
Source: International Congress 2019 – Interventional pulmonology: diagnostic techniques and obstructive airway disease
Year: 2019
Alpha-1 antitrypsin deficiency in patients with COPD/emphysema, bronchiectasis and asthma
Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases
Year: 2020
Comparison of exercise training responses in COPD patients with and without Alpha-1 antitrypsin deficiency
Source: International Congress 2018 – Latest advances in pulmonary rehabilitation assessment and content
Year: 2018
Effects of a-1 antitrypsin augmentation therapy and a-1 antitrypsin deficiency in pneumococcal pneumonia in mice
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019
Therapeutic efficacy of alpha-1 antitrypsin (AAT) augmentation therapy on the loss of lung tissue: an integrated analysis
Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD
Year: 2008
Alpha-1 antitrypsin deficiency and pulmonary morbidity in patients with primary immunodeficiency disease: A single center experience
Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Year: 2018
Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease.
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019
Patients with Alpha-1 antitrypsin Deficiency due to Null mutations have clinical peculiarities and should require personalized pulmonary management
Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept